Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) Melero, I., Gangadhar, T. C., Kohrt, H., Segal, N., Logan, T., Urba, W., Hodi, F., Ott, P., Perez-Gracia, J., Wolchok, J. D., Shah, A., Kurland, J. F., Cohen, L. J., Levy, R., Wigginton, J. M., Goldberg, S. M. AMER SOC CLINICAL ONCOLOGY. 2013
View details for Web of Science ID 000335419605401